Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Non-randomized,Fixed-sequence Crossover Study to Investigate the Effects of a Proton Pump Inhibitor on the Pharmacokinetics of Elinzanetant (BAY 3427080) as Well as Assessment of the Absolute Bioavailability of Elinzanetant Using a Single Intravenous Microtracer Dose of [13C5]BAY 3427080 in Male and Female Healthy Participants

NCT05061563 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05061563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05061563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Non-randomized,Fixed-sequence Crossover Study to Investigate the Effects of a Proton Pump Inhibitor on the Pharmacokinetics of Elinzanetant (BAY 3427080) as Well as Assessment of the Absolute Bioavailability of Elinzanetant Using a Single Intravenous Microtracer Dose of [13C5]BAY 3427080 in Male and Female Healthy Participants
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2021
Completion date
February 23, 2022
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hot flashes, vasomotor symptoms as a sex hormone-dependent disorder in women and men